StemCells, Inc. to Participate at 2014 Regen Med Investor Day in New York

StemCells, Inc. to Participate at 2014 Regen Med Investor Day in New York

President and CEO Martin McGlynn Will Present an Update on the Company's
Programs, Pipeline and Operations

NEWARK, Calif., March 10, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc.
(Nasdaq:STEM) announced today that Martin McGlynn will present at the 2nd
Annual Regen Med Investor Day, Wednesday, March 26, 2014, at 3:30 pm EDT at
the Metropolitan Club, One East 60th Street, in New York City. Mr. McGlynn is
scheduled to present an update on the Company's programs, pipeline and

Organized by the Alliance for Regenerative Medicine (ARM) in partnership with
leading financial firms Maxim Group and Piper Jaffray, this one-day investor
conference focuses exclusively on the regenerative medicine and advanced
therapies sector. The event includes clinical and commercial experts who will
be available to address specific questions regarding the outlook for the
industry, as well as offer insight into how regenerative medicine products
could impact the standard of care in key therapeutic areas. The program will
include talks by key opinion leaders in the industry, life science investment
experts and analysts as well as presentations by more than 30 leading
companies from across the globe.

A live-streaming webcast of all panels and company presentations will be
available at: and will be published on
the event's website shortly after the conference.

A replay will also be accessible for 90 days on the StemCells, Inc. website,

Attendance at this event is for credentialed investors and members of the
media only. If you are interested in attending, please contact Laura Parsons
at Please visit for
more information.

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization
of cell-based therapeutics and tools for use in stem cell-based research and
drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC®
cells (purified human neural stem cells), is currently in development as a
potential treatment for a broad range of central nervous system disorders.In
a PhaseI clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal
myelination disorder in children, the Company has shown preliminary evidence
of progressive and durable donor-derived myelination in all four patients
transplanted with HuCNS-SC cells.The Company is conducting a Phase I/II
clinical trial in chronic spinal cord injury in Switzerland, Canada and the
United States, and has reported positive interim data for the first three
patients.The Company is also conducting a Phase I/II clinical trial in dry
age-related macular degeneration (AMD) in the United States. In addition, the
Company is pursuing preclinical studies in Alzheimer's disease, with support
from the California Institute for Regenerative Medicine (CIRM).StemCells
also markets stem cell research products, including media and reagents, under
the SC Proven® brand.Further information about StemCells is available at

Apart from statements of historical fact, the text of this press release
constitutes forward-looking statements within the meaning of the Securities
Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended,
and is subject to the safe harbors created therein.These statements include,
but are not limited to, the prospect for screening and then enrolling
additional patients with incomplete spinal cord injury; the prospect for
evaluating trial patients for changes in their sensation, motor function and
bowel/bladder function; the potential of the Company's HuCNS-SC cells to treat
spinal cord injury and other central nervous system diseases and disorders;
and the future business operations of the Company. These forward-looking
statements speak only as of the date of this news release. The Company does
not undertake to update any of these forward-looking statements to reflect
events or circumstances that occur after the date hereof. Such statements
reflect management's current views and are based on certain assumptions that
may or may not ultimately prove valid. The Company's actual results may vary
materially from those contemplated in such forward-looking statements due to
risks and uncertainties to which the Company is subject, including the fact
that additional trials will be required to demonstrate the safety and efficacy
of the Company's HuCNS-SC cells for the treatment of any disease or disorder;
uncertainty as to whether applicable regulatory agencies will permit the
Company to continue clinical testing in spinal cord injury or in future
clinical trials of proposed therapies for other diseases or conditions;
uncertainties regarding the Company's ability to obtain the increased capital
resources needed to continue its current and planned research and development
operations; uncertainty as to whether HuCNS-SC cells and any products that may
be generated in the future in the Company's cell-based programs will prove
safe and clinically effective and not cause tumors or other adverse side
effects; and other factors that are described under the heading "Risk Factors"
in the Company's Annual Report on Form 10-K for the year ended December 31,
2012, and in its subsequent reports on Form 10-Q and Form 8-K.

CONTACT: Greg Schiffman
         StemCells, Inc.
         Chief Financial Officer
         (510) 456-4128
         Andrea Flynn
         Russo Partners
         (646) 942-5631

company logo
Press spacebar to pause and continue. Press esc to stop.